While in possession of a token biosimilar portfolio and pipeline, Sanofi has made it clear that its R&D dollars are unlikely to be spent on biosimilars, six months after reshaping its pipeline by exiting diabetes and cardiovascular diseases research.
Sanofi’s global head of research and development, John Reed, has described biosimilars as an “enormous distraction” for a company pursuing novel therapies.
While several Big Pharma companies have over the last decade enjoyed successes juggling a biosimilars unit with a much larger...
Shortly after filing its lead candidate for ADHD through the FDA’s 505(b)(2) hybrid new drug application pathway, Cingulate has appointed interim leadership after placing chairman and CEO Shane Schaffer on administrative leave over legal matters unrelated to the company.
Roche and its Genentech subsidiary have sued Shanghai Henlius Biotech and commercialization partner Organon in the US, alleging infringement of 24 patents covering Perjeta (pertuzumab). The litigation follows Roche’s recent disclosure that biosimilars to Perjeta could launch as soon as 2026.
Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.
